Full Text View
Tabular View
No Study Results Posted
Related Studies
A 14-Week, Multi-Center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.
This study has been completed.
First Received: January 29, 2008   Last Updated: July 9, 2009   History of Changes
Sponsor: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov Identifier: NCT00612170
  Purpose

This is a study to investigate the effectiveness and safety of [S,S]-Reboxetine in relieving the symptoms of Fibromyalgia in patients. A previous study demonstrated clinically meaningful treatment effects in fibromyalgia, based on pain and functional endpoints.


Condition Intervention Phase
Fibromyalgia
Drug: [S,S]-Reboxetine
Drug: Placebo
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study
Official Title: A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily (O.D.) in Patients With Fibromyalgia

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Change from baseline in the endpoint mean pain score [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Fibromyalgia Impact Questionnaire [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline in the endpoint mean sleep interference score [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Patient Global Impression of Change [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Multidimensional Assessment of Fatigue [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Hospital Anxiety and Depression Scale [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Short Form 36 [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Sheehan Disability Score [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Pain Visual Analogue Scale [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]

Enrollment: 1129
Study Start Date: December 2007
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
3: Experimental Drug: [S,S]-Reboxetine
10 mg oral tablet once a day dosing
4: Sham Comparator Drug: Placebo
0 mg oral tablet once a day dosing
1: Experimental Drug: [S,S]-Reboxetine
4 mg oral tablet once a day dosing
2: Experimental Drug: [S,S]-Reboxetine
8 mg oral tablet once a day dosing

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female of any race, at least 18 years of age
  • Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)

Exclusion Criteria:

  • Patients with other severe pain (eg, Diabetic Peripheral Neuropathy and PostHerpetic Neuralgia) that may confound assessment or self evaluation of the pain associated with fibromyalgia
  • Patients with any autoimmune rheumatic disorder, non-focal rheumatic disease (other than fibromyalgia), active infection, or untreated endocrine disorder
  • A current or recent diagnosis (last 6 months) or episode of major depressive disorder, dysthymia and/or uncontrolled depression
  • History of mania, hypomania, other psychotic disorder, or current mood disorder with psychotic features
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00612170

  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site
Birmingham, Alabama, United States, 35242
Pfizer Investigational Site
Tallassee, Alabama, United States, 36078
Pfizer Investigational Site
Huntsville, Alabama, United States, 35802
United States, Arizona
Pfizer Investigational Site
Phoenix, Arizona, United States, 85023
Pfizer Investigational Site
Tucson, Arizona, United States, 85741
Pfizer Investigational Site
Chandler, Arizona, United States, 85225
United States, California
Pfizer Investigational Site
Lafayette, California, United States, 94549
Pfizer Investigational Site
Fullerton, California, United States, 92835
Pfizer Investigational Site
Carmichael, California, United States, 95608
Pfizer Investigational Site
Santa Ana, California, United States, 92705
Pfizer Investigational Site
Roseville, California, United States, 95661
Pfizer Investigational Site
Elk Grove, California, United States, 95758
Pfizer Investigational Site
Sacramento, California, United States, 95816
Pfizer Investigational Site
Oceanside, California, United States, 92056
Pfizer Investigational Site
Northridge, California, United States, 91325
Pfizer Investigational Site
Sacramento, California, United States, 95823
Pfizer Investigational Site
San Jose, California, United States, 95124
United States, Connecticut
Pfizer Investigational Site
New London, Connecticut, United States, 06320
United States, Florida
Pfizer Investigational Site
West Palm Beach, Florida, United States, 33407
Pfizer Investigational Site
St. Petersburg, Florida, United States, 33709
Pfizer Investigational Site
Brooksville, Florida, United States, 34601
Pfizer Investigational Site
Tampa, Florida, United States, 33606
Pfizer Investigational Site
Sarasota, Florida, United States, 34233
Pfizer Investigational Site
Tampa, Florida, United States, 33614
Pfizer Investigational Site
Sunrise, Florida, United States, 33351
Pfizer Investigational Site
Winter Haven, Florida, United States, 33880
Pfizer Investigational Site
Venice, Florida, United States, 34292
Pfizer Investigational Site
Ocala, Florida, United States, 34471
Pfizer Investigational Site
Ocala, Florida, United States, 34474
Pfizer Investigational Site
Jacksonville, Florida, United States, 32223
Pfizer Investigational Site
Jacksonville, Florida, United States, 32257
Pfizer Investigational Site
Jacksonville, Florida, United States, 32216
Pfizer Investigational Site
Jacksonville, Florida, United States, 32205
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30328
Pfizer Investigational Site
Atlanta, Georgia, United States, 30342
United States, Illinois
Pfizer Investigational Site
Gurnee, Illinois, United States, 60031
Pfizer Investigational Site
Moline, Illinois, United States, 61265
Pfizer Investigational Site
Oak Brook, Illinois, United States, 60523
Pfizer Investigational Site
Aurora, Illinois, United States, 60504
United States, Indiana
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46250
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46260
United States, Iowa
Pfizer Investigational Site
Dubuque, Iowa, United States, 52001
United States, Kansas
Pfizer Investigational Site
Overland Park, Kansas, United States, 66212
Pfizer Investigational Site
Pratt, Kansas, United States, 67124
Pfizer Investigational Site
Overland Park, Kansas, United States, 66215
United States, Kentucky
Pfizer Investigational Site
Mt. Sterling, Kentucky, United States, 40353
Pfizer Investigational Site
Louisville, Kentucky, United States, 40213
Pfizer Investigational Site
Lexington, Kentucky, United States, 40509
Pfizer Investigational Site
Madisonville, Kentucky, United States, 42431
United States, Louisiana
Pfizer Investigational Site
Baton Rouge, Louisiana, United States, 70809
United States, Maryland
Pfizer Investigational Site
Wheaton, Maryland, United States, 20902
United States, Massachusetts
Pfizer Investigational Site
Fall River, Massachusetts, United States, 02720
Pfizer Investigational Site
Boston, Massachusetts, United States, 02135
Pfizer Investigational Site
Watertown, Massachusetts, United States, 02472
Pfizer Investigational Site
North Dartmouth, Massachusetts, United States, 02747
Pfizer Investigational Site
Brockton, Massachusetts, United States, 02301
Pfizer Investigational Site
Worcester, Massachusetts, United States, 01610
Pfizer Investigational Site
Wellesley Hills, Massachusetts, United States, 02481-2106
United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48103
United States, Minnesota
Pfizer Investigational Site
Rochester, Minnesota, United States, 55905
Pfizer Investigational Site
Chaska, Minnesota, United States, 55318
Pfizer Investigational Site
Edina, Minnesota, United States, 55435
United States, Mississippi
Pfizer Investigational Site
Olive Branch, Mississippi, United States, 38654
United States, Missouri
Pfizer Investigational Site
Columbia, Missouri, United States, 65203
Pfizer Investigational Site
Columbia, Missouri, United States, 65212
Pfizer Investigational Site
St. Louis, Missouri, United States, 63141
Pfizer Investigational Site
Jefferson City, Missouri, United States, 65109
United States, Nebraska
Pfizer Investigational Site
Omaha, Nebraska, United States, 68134
United States, Nevada
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89119
Pfizer Investigational Site
Henderson, Nevada, United States, 89014
Pfizer Investigational Site
Henderson, Nevada, United States, 89015
United States, New Mexico
Pfizer Investigational Site
Albuquerque, New Mexico, United States, 87109
United States, New York
Pfizer Investigational Site
New York, New York, United States, 10022-1009
Pfizer Investigational Site
Albany, New York, United States, 12205
Pfizer Investigational Site
Brooklyn, New York, United States, 11235
Pfizer Investigational Site
Bronx, New York, United States, 10454
Pfizer Investigational Site
New York, New York, United States, 10021
Pfizer Investigational Site
Rochester, New York, United States, 14610
Pfizer Investigational Site
Rochester, New York, United States, 14618
United States, North Carolina
Pfizer Investigational Site
Salisbury, North Carolina, United States, 28144
Pfizer Investigational Site
Charlotte, North Carolina, United States, 28209-3734
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45219
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45249
Pfizer Investigational Site
Toledo, Ohio, United States, 43623
Pfizer Investigational Site
Columbus, Ohio, United States, 43213
Pfizer Investigational Site
Cleveland, Ohio, United States, 44122
Pfizer Investigational Site
Dayton, Ohio, United States, 45408
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45227
United States, Oklahoma
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73103
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73112
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States, 97219
Pfizer Investigational Site
Bend, Oregon, United States, 97701
Pfizer Investigational Site
Medford, Oregon, United States, 97504
Pfizer Investigational Site
Eugene, Oregon, United States, 97401
Pfizer Investigational Site
Portland, Oregon, United States, 97239
United States, Pennsylvania
Pfizer Investigational Site
Bethlehem, Pennsylvania, United States, 18015
Pfizer Investigational Site
Bridgeville, Pennsylvania, United States, 15017
Pfizer Investigational Site
West Reading, Pennsylvania, United States, 19611-1124
Pfizer Investigational Site
Duncansville, Pennsylvania, United States, 16635
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15216
Pfizer Investigational Site
Altoona, Pennsylvania, United States, 16602
Pfizer Investigational Site
Willow Grove, Pennsylvania, United States, 19090
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15243
United States, Rhode Island
Pfizer Investigational Site
Cumberland, Rhode Island, United States, 02864
Pfizer Investigational Site
Warwick, Rhode Island, United States, 02886
Pfizer Investigational Site
Lincoln, Rhode Island, United States, 02865
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States, 29412
United States, Tennessee
Pfizer Investigational Site
Nashville, Tennessee, United States, 37203
Pfizer Investigational Site
Bristol, Tennessee, United States, 37620
Pfizer Investigational Site
Kingsport, Tennessee, United States, 37660
Pfizer Investigational Site
Milan, Tennessee, United States, 38358
Pfizer Investigational Site
Jackson, Tennessee, United States, 38305
Pfizer Investigational Site
Johnson City, Tennessee, United States, 37601
United States, Texas
Pfizer Investigational Site
Dallas, Texas, United States, 75231
Pfizer Investigational Site
San Antonio, Texas, United States, 78213
Pfizer Investigational Site
Austin, Texas, United States, 78759
Pfizer Investigational Site
Lake Jackson, Texas, United States, 77566
Pfizer Investigational Site
Austin, Texas, United States, 78758
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
Pfizer Investigational Site
DeSoto, Texas, United States, 75115
Pfizer Investigational Site
Bryan, Texas, United States, 77802
Pfizer Investigational Site
Nassau Bay, Texas, United States, 77058
Pfizer Investigational Site
Beaumont, Texas, United States, 77701
Pfizer Investigational Site
Beaumont, Texas, United States, 77706
Pfizer Investigational Site
Houston, Texas, United States, 77063
United States, Utah
Pfizer Investigational Site
Ogden, Utah, United States, 84405
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84107
United States, Virginia
Pfizer Investigational Site
Viginia Beach, Virginia, United States, 23455
Pfizer Investigational Site
Charlottesville, Virginia, United States, 22911
Pfizer Investigational Site
Arlington, Virginia, United States, 22205
Pfizer Investigational Site
Virginia Beach, Virginia, United States, 23455
United States, Washington
Pfizer Investigational Site
Kirkland, Washington, United States, 98033
Pfizer Investigational Site
Seattle, Washington, United States, 98104
Pfizer Investigational Site
Seattle, Washington, United States, 98122
Pfizer Investigational Site
Spokane, Washington, United States, 99216
United States, Wisconsin
Pfizer Investigational Site
Milwaukee, Wisconsin, United States, 53209
Pfizer Investigational Site
Oregon, Wisconsin, United States, 53575
Canada
Pfizer Investigational Site
Quebec, Canada, G1V 3M7
Canada, British Columbia
Pfizer Investigational Site
Kelowna, British Columbia, Canada, V1Y 2H4
Canada, New Brunswick
Pfizer Investigational Site
Bathurst, New Brunswick, Canada, E2A 4X7
Pfizer Investigational Site
Moncton, New Brunswick, Canada, E1G 1A7
Canada, Ontario
Pfizer Investigational Site
Toronto, Ontario, Canada, M3H 5S4
Pfizer Investigational Site
Hawkesbury, Ontario, Canada, K6A 1A1
Pfizer Investigational Site
Toronto, Ontario, Canada, M9W 4L6
Canada, Quebec
Pfizer Investigational Site
Sherbrooke, Quebec, Canada, J1H 1Z1
Pfizer Investigational Site
Pointe Claire, Quebec, Canada, H9R 3J1
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Inc ( Director, Clinical Trial Disclosure Group )
Study ID Numbers: A6061043, A6061043
Study First Received: January 29, 2008
Last Updated: July 9, 2009
ClinicalTrials.gov Identifier: NCT00612170     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Phase 3, safety and efficacy study, [S,S[-Reboxetine, Fibromyalgia

Additional relevant MeSH terms:
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Fibromyalgia
Myofascial Pain Syndromes
Physiological Effects of Drugs
Nervous System Diseases
Psychotropic Drugs
Rheumatic Diseases
Pharmacologic Actions
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Therapeutic Uses
Central Nervous System Agents
Antidepressive Agents
Reboxetine

ClinicalTrials.gov processed this record on November 27, 2009